The potential role of insulin-like growth factor 1, insulin-like growth factor binding protein 3 and bone mineral density in patients with chronic hepatitis C virus in Cairo, Egypt

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 104, Issue 6, 2010, Pages 429-432

  Raslan, Hala M ^a   Elhosary, Yasser ^a   Ezzat, Wafaa M ^a   Rasheed, Enas Abdel ^a   Rasheed, Maha A ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Bone mineral density; Egypt; Insulin like growth factor 1; Insulin like growth factor binding protein 3; Liver cirrhosis; Osteoporosis

Indexed keywords

SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LUMBAR SPINE; MALE; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SCHISTOSOMA;

ADULT; AGED; BODY MASS INDEX; BONE DENSITY; CASE-CONTROL STUDIES; EGYPT; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS; STATISTICS AS TOPIC;

HEPATITIS C VIRUS;

EID: 77952672955     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2010.01.012     Document Type: Article

References (30)

1. Stellon A.J., Webb A., Compston J.E. Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis. Gut 1988, 29:378-384.
2. Lalor B.C., France M.W., Powel D., Adams P.H., Counichan T.B. Bone and mineral metabolism and chronic alcohol abuse. QJ Med 1986, 59:497-511.
3. Stellon A.J., Webb A., Compston J., Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987, 7:137-142.
4. Olsson R., Johansson C., Lindstedt G., Mellström D. Risk factor for bone loss in chronic active hepatitis and primary biliary cirrhosis. Scand J Gastroenterol 1994, 29:743-756.
5. Diamond T., Stiel D., Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J Bone Miner Res 1991, 6:39-43.
6. Diamond T., Stiel D., Lunzre M., Wilkinson M., Roche J., Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1999, 31:82-87.
7. McCaughen G.W., Feller E.B. Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig Dis 1994, 12:223-231.
8. Janssen J.A., Lamberts S.W. The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?. Eur J Endocrinol 2002, 146:467-477.
9. Tritos N.A., Mantzoros C.S. Recombinant human growth hormone: old and novel uses. Am J Med 1998, 105:44-57.
10. Eriksen E.F., Kasssem M., Langdahl B. Growth hormone, insulin like growth factors and bone remodeling. Eur J Clin Invest 1996, 26:525-534.
11. Zapf J., Kiefer M., Merryweather J. Isolation from adult human serum of four insulin-like growth factor (IGF) binding proteins and molecular cloning of one of them that is increased by IGF I administration and in extrapancreatic tumor hypoglycemia. J Biol Chem 1990, 265:14892-14898.
12. Christenson R.H. Biochemical markers of bone metabolism: an overview. Clin Biochem 1997, 30:573-593.
13. Teale J.D. The diagnostic application of serum growth hormone, insulin-like growth factor (IGF), and IGF binding protein measurements. J Int Fed Clin Chem 1995, 6:164-168.
14. Lind D.A., Marchal W.G., Wathen S.A. Statistical techniques in business and economics 2005, McGraw-Hill Irwin, Boston, MA. 12th ed.
15. Stefano J.T., Corrêa-Giannella M.L., Ribeiro C.M., Ferrei V., Massarollo C., Machado M.C., et al. Increased hepatic expression of insulin-like growth factor-1 in chronic hepatitis C. World J Gastroenterol 2006, 12:3821-3828.
16. Donaghy A., Delhanty P., Ho K., Williams R., Baxter R. Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. J Hepatol 2002, 36:751-758.
17. Donaghy A., Ross R., Gimson A., Hughes S., Holly J., Williams R. Growth hormone, insulin-like growth factor-1, and insulin-like growth factor binding proteins 1 and 3 in chronic liver disease. Hepatol 1995, 21:680-688.
18. Shaarawy M., Fikry A., Massoud B., Lotfy S. Insulin-like growth factor binding protein-3: A novel biomarker for the assessement of the synthetic capacity of hepatocytes in liver cirrhosis. J Clin Endocrinol Metab 1998, 83:3316-3319.
19. Monegal A., Navasa M., Guanabens N., Peris P., Martinez de Osaba M.J., Rimola A., et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 1997, 60:148-154.
20. Gallego-Rojo F.J., Conzales-Calvin J.L., Munoz-Torres M., Mundi J.L., Fernandez-Perez R., Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor l, and bone turnover markers in viral cirrhosis. Hepatology 1998, 28:695-699.
21. Sezgin M., Çimen B., Ranik A., As I., Erçetin N., Incel N., Şahin G. Serum IGF- 1 and IGFBP-3 levels in middle aged Turkish males: relationships with bone mineral density and markers of bone turnover (male osteoporosis and IGF-1, IGFBP-3). Osteoporoz Dünyasindan 2007, 13:37-43.
22. Wuster C., Blum W.F., Schlemilch S., Ranke M.B., Ziegler R. Decreased serum levels of insulin-like growth factors and IGF binding protein 3 in osteoporosis. J Intern Med 1993, 234:249-255.
23. Rusinska A., Chlebna-Sokol D. Involvement of IGF-1 in the development of idiopathic osteoporosis in children. Clin Chim Acta 2006, 366:257-263.
24. Lasco A., Morabito N., Gaudio A., Crisafulli A., Meo A., Denuzzo G., et al. Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis. Endocrinol Invest 2002, 25:338-344.
25. Szulc P., Joly Pharaboz M., Marchand F., Delmas P. Insulin like growth factor 1 is a determinant of bone mineral density in men less than 60 years of age: MINOS study. Calcif Tissue Int 2004, 74:322-329.
26. Ueland T., Brixen K., Mosekilde L., Mosekilde L., Flyvbjerg A., Bollerslev J. Age related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. J Clin Endocrinol Metab 2003, 88:1014-1018.
27. Tanaka H., Moriwake T., Matsuoka Y., Nakamura T., Seino Y. Potential role of rhIGF/IGFBP-3 in maintaining skeletal mass in space. Bone 1998, 22(Suppl 1):145S-147S.
28. Canalis E. Insulin-like growth factors and osteoporosis. Bone 1997, 21:215-216.
29. Zofhova I. Pathophysiological and clinical importance of insulin like growth factor-1 with respect to bone metabolism. Physiol. Res. 2003, 52:657-659.
30. Niedźwiedzkal A. Insulin-like growth factor1 (somatomedin C) and its binding proteins 3 in children with special consideration of diabetes (in Polish). Endokrynol Diabetol i Ch Przemiamy Materii Wieku Rozwojowego 2000, 6:51-58.